This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Isabelle Scarabin
Business Licensing Officer at Bayer


Isabelle Scarabin is a Director, Business Development & Licensing Officer, at the Pharmaceuticals division of Bayer AG. She leads the development of strategies and projects as related to business development for New Platforms (Cell & Gene Therapy), Ophthalmology and Hemophilia and joined the team in November 2021.

Isabelle is a senior Business Development manager with more than 15 years of experience in the Healthcare industry, including more than eight years in gene therapy, optogenetics and ophthalmology. She was the Business Development Director at GenSight Biologics, a French public company, developing and commercializing gene therapies for rare degenerative diseases. She has acquired significant expertise in scouting, due diligence, negotiation, and deal execution for a broad spectrum of type of transactions: collaboration/alliance/in- & out- licensing/M&A as well as public funding raising.

Prior to GenSight, Isabelle had over 10 years of experience in several positions in non-profit organizations and has vast experience in consulting in business development for biotech firms. She started her career in innovation management at Resources in Innovation and in new vaccine launch management and strategic marketing at Sanofi Pasteur MSD.

Isabelle received an Engineering master’s degree in Biochemistry from the National Institute of Applied Sciences (INSA) Lyon and a master’s degree in Innovation & Technology Management from EMLyon Business School.

Agenda Sessions

  • Choose the right ingredients for successful collaborations between biotech startups and big pharma